Sickle Cell Disease

Siklos Now Available for Pediatric Patients With Sickle Cell Anemia

By August 21, 2018

Hydroxyurea, an antimetabolite, is thought to cause an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.

Olinciguat Granted Orphan Drug Status for Sickle Cell Disease

By June 08, 2018

Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.

Siklos Approved for Pediatric Patients With Sickle Cell Anemia

By December 21, 2017

This is the first FDA approval of hydroxyurea for use in pediatric patients with sickle cell disease.

Sickle Cell Disease Treatment Endari Soon to Be Available

By December 11, 2017

Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.